You can write in Portuguese, English, Spanish or French. The search doesn't link to accents or uppercase letters, separates the words (all must appear) and also searches for the equivalent word in other languages: "transplant" finds "transplant" and "trasplante". Searches in the original titles, translated titles into Portuguese, descriptions and abstracts. MielomaAI.
In the last 3 months. From the older news, only the title and link remain in the archive. Those that have about 1 year may no longer be up to date
Looking for words: ensaios + clinicos. Saltar para: Recent news (9) · My Hematologia (10) · explicações (4) · arquivo (3)
CAR-NK Therapy for Multiple Myeloma: A Clinical Trial Success StoryHealth US News · 20:41 Doentes e associaçõesDiscover how an innovative CAR-NK cell therapy clinical trial led to complete remission for a patient facing relapsed multiple myeloma.
Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)Nature (Reino Unido) · 09:29 InvestigaçãoReino Unido
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaBusiness Wire (Internacional) · 07:00 TratamentosInternacional- BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trialClinical Trials Arena (China) · 07:00 InvestigaçãoChina
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointFierce Biotech (EUA) · 07:00 InvestigaçãoEUA
https://rarecancernews.com/news/under-the-skin-myeloma-treatment-linked-better-survival-study/ Interesting article.Facebook (Internacional) · 16:42 Doentes e associaçõesInternacional
MRD Ready to Guide Multiple Myeloma Treatment Decisions?MedPage Today · 17:32 Tratamentos'MRD is becoming a very valuable tool, but it's not an exclusive tool,' says expert
Lola Manterola, from CRIS Against Cancer, Receives Research Award at the Woman 2026 Awards: the woman who turned her experience with cancer into an opportunity for thousands of patients.Woman Madame Figaro · 12:41 Patients and associationsESMultiple myeloma survivor, has turned his experience with the disease into a firm commitment to drive oncology research and give hope to thousands of patients. For them, it is our 2026 Woman Awards Research Prize.
NCCN Guidelines Position CAR T Cells in Early Relapsed Multiple MyelomaCancerNetwork (EUA) · 07:00 Acesso e saúde públicaEUAMatthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early relapsed multiple myeloma.
Click on an article to open it on the side with the summary. MielomaAI And the link to the source.
Clinical trial DREAMM-2 and real-life data on belantamab mafodotina are “a beacon of hope” for patients with MM and >4 lines of treatment.InterviewsMy Hematologia · November 16, 2022The DREAMM-2 clinical trial showed that a significant number of patients with multiple myeloma, who had already received many other therapies, achieved a positive response to treatment with belantamab mafodotina. Read more →
Best of 2020: Stay up to date with the latest clinical advances in Haematology-OncologyEventsMy Hematologia · February 1, 2021This event, called Best of 2020, was created to help healthcare professionals understand the latest advances in the treatment of various types of blood cancer, such as multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström macroglobulinemia. Read more →
Multiple myeloma: a combination strategy of multiple mechanisms of action allows for sustained disease control.InterviewsMy Hematologia · November 8, 2024This article reports on a presentation about the use of bispecific anti-BCMA drugs in the treatment of multiple myeloma, particularly in patients who have already received other treatments such as proteasome inhibitors or anti-CD38 antibodies. Read more →
High-risk multiple myeloma: is there an optimal therapeutic approach?NewsMy Hematologia · May 22, 2023This article addresses the issue of the best therapeutic approach for high-risk multiple myeloma, based on the clinical case of a 61-year-old patient. The patient presented high-risk characteristics, such as a high concentration of free light chains, genetic alterations in the bone marrow, and an initial response to treatment with bortezomib, lenalidomide, and dexamethasone. Read more →
Treatment of multiple myeloma: The European Union grants conditional market authorization for teclistamab.NewsMy Hematologia · September 9, 2022Teclistamab is a new drug approved by the European Union to treat multiple myeloma in advanced stages when other treatments have not worked. It is an antibody that acts on two parts of the myeloma cells, helping to destroy the cancerous cells. Read more →
GSK's Commitment to Hematology: Ambition for Multiple Myeloma PatientsInterviewsMy Hematologia · 6 Sep 2022** Read more →
GSK shared latest oncology advances at the ASCO and EHA meetings.NewsMy Hematologia · 20 Jun 2022** Read more →
Incorporating this drug into a early phase of MM will have significant advantages in terms of responses and survival for these patients.InterviewsMy Hematologia · May 12, 2022Daratumumab is a new medication that is being used in the treatment of multiple myeloma (MM) as part of an initial treatment plan. This medication, in combination with other existing treatments, has shown very positive results in clinical trials. Read more →
Approved carfilzomib in combination with dexamethasoneNewsMy Hematologia · August 3, 2020The National Authority of Medicines and Health Products (Infarmed) has decided that the drug Kyprolis, which combines carfilzomib and dexamethasone, can be used to treat people with multiple myeloma who have already undergone other therapies. Read more →
Oral proteasome inhibitor allows for prolonged therapy in real life.NewsMy Hematologia · June 19, 2020** Read more →
- Clinical trials
- Studies comparing a new treatment with the best existing treatment may provide access to medications before approval. Participation is voluntary.
- Smouldering myeloma
- Protein M of 3 g/dL or more, or 10% to 60% plasma cells in the bone marrow, but without CRAB signs. How to manage or treat: Close monitoring (every 3 or 6 months) with imaging tests. In high-risk latency, daratumumab may be administered or entry into a clinical trial may be considered. Risk: Approximately 10% per year during the first 5 years. High risk when 2 or 3 of the following are present: more than 20% plasma cells, protein M above 2 g/dL, light chain ratio above 20. See the film "Types of myeloma" →
- Extramedullary Disease
- Multiple myeloma with tumors in organs or soft tissues (skin, liver, lymph nodes, nervous system), in diagnosis or, more frequently, in relapses. How it is managed or treated: Intensive treatment; CAR-T and bispecifics are options in relapse; clinical trials. Risk: High risk. See the film "Types of myeloma" →
- Multiple myeloma
- 5% or more of plasma cells circulating in the blood. Primary (at the very beginning) or secondary (in a relapse). How to manage it: Intensive and rapid treatment; transplant for those who can; clinical trials. Risk: Very high risk: the most aggressive form. See the film "Types of myeloma" →
Patients and associations
- Innovent Biologics announced that the first patient has received the initial dose in a Phase 3 clinical trial of IBI3003 (a tri-specific monoclonal antibody targeting GPRC5D/BCMA/CD3) for the treatment of multiple myeloma. ↗ · PR Newswire · 21/06/2026
Research
- Indapta Therapeutics announces collaboration with Sanofi in a clinical trial for multiple myeloma ↗ about 1 year · Business Wire · 06/12/2024
- Research and clinical trials for myeloma ↗ 8 years · Cancer Research UK · 29/06/2018
